ArticleVeterinary research communications2025
Effects of high-dose alacepril on the renin-angiotensin-aldosterone system and autonomic nervous system function in healthy dogs.
Article in Veterinary research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the effects of low-dose and high-dose alacepril on the renin-angiotensin-aldosterone system (RAAS) and autonomic nervous system in healthy dogs. Six Beagle dogs received low-dose (2.0 mg/kg/day) or high-dose (6.0 mg/kg/day) alacepril for 4 weeks. Blood pressure, the urinary aldosterone-to-creatinine ratio (UAld: Cre), echocardiographic variables, and heart rate variability were assessed pre- and post-treatment. High-dose alacepril reduced blood pressure and left ventricular dimensions, indicating a reduced preload and afterload. Heart rate variability analysis showed an increased percentage of successive normal-to-normal interval differences of > 50 ms, suggesting enhanced parasympathetic activity despite detecting no changes in heart rate. UAld: Cre was not significantly different. Low-dose alacepril had no significant effect on any of these variables. In conclusion, high-dose alacepril demonstrates antihypertensive effects and enhances parasympathetic activity, which may confer cardiovascular benefits. It reduces blood pressure, decreases left ventricular preload, and increases parasympathetic activity. However, both high-dose and low-dose alacepril showed incomplete RAAS suppression. These findings highlight the need for further research to clarify its therapeutic potential in heart failure and hypertension.
Indexed as
Identifiers
40459695What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.